NA
AZN icon

NewEdge Advisors’s AstraZeneca AZN Stock Holding History

NewEdge Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.48M Buy
39,462
+621
+2% +$117K 0.02% 605
2026
Q1 		$7.66M Sell
38,841
-6,065
-14% -$1.17M 0.03% 532
2025
Q4 		$8.26M Buy
44,906
+13,329
+42% +$2.34M 0.03% 497
2025
Q3 		$4.85M Sell
31,577
-5,246
-14% -$794K 0.02% 643
2025
Q2 		$5.15M Sell
36,823
-118
-0.3% -$16.5K 0.03% 562
2025
Q1 		$5.43M Buy
36,941
+707
+2% +$102K 0.03% 482
2024
Q4 		$4.75M Buy
36,234
+8,860
+32% +$1.24M 0.03% 515
2024
Q3 		$4.27M Buy
27,374
+2,579
+10% +$416K 0.03% 535
2024
Q2 		$3.87M Buy
24,795
+2,890
+13% +$435K 0.03% 528
2024
Q1 		$2.97M Buy
21,905
+2,979
+16% +$394K 0.03% 550
2023
Q4 		$2.54M Buy
18,926
+1,713
+10% +$223K 0.02% 582
2023
Q3 		$2.33M Buy
17,213
+1,501
+10% +$205K 0.03% 554
2023
Q2 		$2.25M Sell
15,712
-585
-4% -$86.1K 0.03% 550
2023
Q1 		$2.26M Sell
16,297
-472
-3% -$63.5K 0.03% 497
2022
Q4 		$491K Buy
16,769
+929
+6% +$117K 0.01% 783
2022
Q3 		$1.74M Buy
15,840
+8
+0.1% +$1.01K 0.03% 466
2022
Q2 		$2.09M Sell
15,832
-8,221
-34% -$1.08M 0.03% 426
2022
Q1 		$3.19M Buy
24,053
+1,313
+6% +$157K 0.05% 323
2021
Q4 		$2.65M Buy
22,740
+565
+3% +$66.5K 0.04% 372
2021
Q3 		$2.66M Sell
22,175
-5,797
-21% -$675K 0.07% 266
2021
Q2 		$3.35M Sell
27,972
-1,517
-5% -$166K 0.09% 221
2021
Q1 		$2.93M Sell
29,489
-132,048
-82% -$13.3M 0.09% 220
2020
Q4 		$16.1M Buy
161,537
+154,477
+2,188% +$16.4M 0.53% 46
2020
Q3 		$774K Buy
+7,060
New +$785K 0.03% 451
2020
Q1 		– Sell
-2,457
Closed -$245K – 799
2019
Q4 		$245K Sell
2,457
-182
-7% -$17.1K 0.01% 719
2019
Q3 		$233K Buy
+2,639
New +$229K 0.01% 705
2017
Q3 		– Sell
-364
Closed -$24.4K – 421
2017
Q2 		$24.4K Buy
+364
New +$23.8K ﹤0.01% 677

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NewEdge Advisors's AZN Position: Q2 2026 in Review

NewEdge Advisors increased its AstraZeneca (AZN) stake by 1.6% in Q2 2026, buying an estimated $117K and bringing the position to 39,462 shares worth $7.48M. The position accounts for 0.02% of the portfolio, ranked #605.

NewEdge Advisors first reported a position in AZN in Q2 2017 and has held it in 27 quarters since. The position peaked at $16.1M in Q4 2020. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • NewEdge Advisors held 39,462 shares of AstraZeneca worth $7.48M as of Q2 2026.
  • NewEdge Advisors bought 621 AstraZeneca shares in Q2 2026, an estimated $117K.
  • AstraZeneca made up 0.02% of NewEdge Advisors's portfolio in Q2 2026, its #605 holding.
  • NewEdge Advisors first reported a position in AstraZeneca in Q2 2017 and has held it in 27 quarters since.
  • NewEdge Advisors's AstraZeneca position peaked at $16.1M in Q4 2020.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.